Zeaxanthin and Omega-3 Fatty Acids: study protocols
3 study groups took Zeaxanthin together with Omega-3 Fatty Acids. These are the doses the studies gave. They are not a recommendation.
Fewer than 5 study groups in one unit match, too few to draw the chart.
Commonly used together
3 of 3 study groups took Zeaxanthin and Omega-3 Fatty Acids with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Lutein | 3 |
3 study groups
| Study | ||||
|---|---|---|---|---|
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 2 mg | 650 mg | 5 years | — |
| Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 2014 · lutein/zeaxanthin and DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified | 2 mg | 1 g | 1789 days | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 2 mg | 650 mg | 5 years | — |